Soligenix stock rallies 400% on positive HyBryte trial results
Soligenix Inc (NASDAQ: SGNX) reported positive interim data from a trial of its HyBryte therapy on Tuesday. HyBryte is the biopharmaceutical firm’s treatment for early-stage cutaneous T-cell lymphoma. Soligenix stock rallied a whopping 400% following the interim results today. Here’s why it matters for Soligenix stock Soligenix has so far enrolled six patients in the